ASCO GI 2025: Danish Study Highlights Efficacy and Safety of Single-Cycle Neoadjuvant Pembrolizumab for Localized dMMR Colon Cancer
Findings from the RESET-C study suggest that a single cycle of neoadjuvant pembrolizumab offers high efficacy and manageable safety for patients with localized dMMR colon cancer, as presented at the ASCO Gastrointestinal Cancers Symposium.